1-4 of 4
Amity Venables
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, Timothy Hughes
Journal: Blood
Blood (2007) 110 (12): 4064–4072.
https://doi.org/10.1182/blood-2007-06-093617
Published: 2007
Includes: Supplemental data
Journal Articles

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Devendra K. Hiwase, MD, Deborah L. White, Verity A. Saunders, Phuong Dang, Amity Venables, Laura Eadie, Steph Zrim, L. Bik To, MD, Junia V. Melo, MD, Timothy P. Hughes, MD
Journal: Blood
Blood (2007) 110 (11): 1937.
https://doi.org/10.1182/blood.V110.11.1937.1937
Published: 2007
Journal Articles

Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib.

Deborah White, Verity Saunders, Phuong Dang, Amity Venables, Steph Zrim, John Reynolds, Steven Quinn, Andrew Zannettino, Timothy Hughes
Journal: Blood
Blood (2006) 108 (11): 738.
https://doi.org/10.1182/blood.V108.11.738.738
Published: 2006
Journal Articles

ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.

Deborah White, Phuong Dang, Amity Venables, Verity Saunders, Stephanie Zrim, Andrew Zannettino, Peter Diamond, Steven Quinn, Luen Bik To, Timothy Hughes
Journal: Blood
Blood (2006) 108 (11): 2144.
https://doi.org/10.1182/blood.V108.11.2144.2144
Published: 2006